Durvalumab (Anti PD-L1) As Monotherapy or in Combination Therapy for Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma ( DLBCL) and Follicular Lymphoma (FL): A Subgroup Analysis from the Phase 1/2 Fusion NHL-001 Global Multicenter Trial

被引：9

作者：

Casulo, Carla ^{[1
]}

Santoro, Armando ^{[2
,3
]}

Ando, Kiyoshi ^{[4
]}

Le Gouill, Steven ^{[5
]}

Ruan, Jia ^{[6
]}

Radford, John ^{[7
,8
]}

Arcaini, Luca ^{[9
,10
]}

Pinto, Antonello ^{[11
]}

Bouabdallah, Reda ^{[12
]}

Izutsu, Koji ^{[13
]}

Rule, Simon ^{[14
]}

Munoz, Javier ^{[15
]}

Casadebaig, Marie-Laure ^{[16
]}

Fox, Brian ^{[17
]}

Rettby, Nils ^{[16
]}

Dell'Aringa, Justine ^{[17
]}

Delarue, Richard ^{[16
]}

Newhall, Kathryn ^{[17
]}

Czuczman, Myron ^{[17
]}

Cartron, Guillaume ^{[18
]}

机构：

[1] Univ Rochester, Med Ctr, Wilmot Canc Inst, Rochester, NY 14642 USA

[2] Humanitas Univ, Rozzano Milan, Italy

[3] Humanitas Clin & Res Ctr, Rozzano Milan, Italy

[4] Tokai Univ, Sch Med, Isehara, Kanagawa, Japan

[5] CHU Nantes, Nantes, France

[6] Weill Cornell Med, New York, NY USA

[7] Univ Manchester, Manchester, Lancs, England

[8] Christie NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England

[9] Fdn IRCCS Policlin San Matteo, Pavia, Italy

[10] Univ Pavia, Pavia, Italy

[11] Fdn G Pascale, Ist Nazl Tumori IRCCS, Naples, Italy

[12] Inst Paoli Calmettes, Marseille, France

[13] Natl Canc Ctr, Dept Hematol, Tokyo, Japan

[14] Univ Plymouth, Plymouth, Devon, England

[15] Banner MD Anderson Canc Ctr, Gilbert, AZ USA

[16] Celgene Int, Boudry, Switzerland

[17] Celgene Corp, Seattle, WA USA

[18] Ctr Hosp Univ Montpellier, Montpellier, France

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-124102

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

5320

引用

页数：5

共 50 条

[21] Global Pivotal Phase 2 Trial of the CD19-Targeted Therapy CTL019 In Adult Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)-An Interim Analysis
Schuster, Stephen
Bishop, Michael R.
Tam, Constantine
Waller, Edmund K.
Borchmann, Peter
McGuirk, Joseph
Jaeger, Ulrich
Jaglowski, Samantha
Andreadis, Charalambos
Westin, Jason
Fleury, Isabelle
Bachanova, Veronika
Foley, Stephen Ronan
Ho, P. Joy
Mielke, Stephan
Magenau, John M.
Holte, Harald
Anak, Oezlem
Pacaud, Lida
Awasthi, Rakesh
Tai, Feng
Salles, Gilles
Maziarz, Richard T.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S373 - S374
[22] Safety and Efficacy Results From Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (Liso-Cel) In Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Abramson, Jeremy
Palomba, M. Lia
Gordon, Leo
Lunning, Matthew
Wang, Michael
Arnason, Jon
Mehta, Amitkumar
Purev, Enkhtsetseg
Maloney, David
Andreadis, Charalambos
Sehgal, Alison
Solomon, Scott
Ghosh, Nilanjan
Albertson, Tina
Garcia, Jacob
Kostic, Aria
Li, Daniel
Kim, Yeonhee
Siddiqi, Tanya
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 215 - 215
[23] PREFERENCE-WEIGHTED HEALTH STATUS IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL) TREATED WITH LISOCABTAGENE MARALEUCEL (LISO-CEL; JCAR017) IN THE ONGOING, MULTICENTER, PHASE 1 TRANSCEND NHL 001 TRIAL
Patrick, D.
Matza, L.
Kim, Y.
Garcia, J.
Dehner, C.
Chung, K. C.
VALUE IN HEALTH, 2019, 22 : S106 - S106
[24] Phase 1/2 Trial of Acalabrutinib Plus Pembrolizumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (08) : 9 - 10
[25] Subgroup analyses of diffuse large B-cell lymphoma (DLBCL) and indolent lymphoma cohorts from a phase Ha study of single-agent MOR208 in patients with relapsed or refractory non-Hodgkin's lymphoma (R-R NHL).
Jurczak, Wojciech
Zinzani, Pier Luigi
Gaidano, Gianluca
Goy, Andre
Provencio, Mariano
Nagy, Zsolt
Robak, Tadeusz
Maddocks, Kamij.
Buske, Christian
Ambarkhane, Sumeet Vijay
Winderlich, Mark
Endell, Jan
Blum, Kristie A.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[26] Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): Responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses.
Davids, Matthew Steven
Seymour, John Francis
Gerecitano, John F.
Kahl, Brad S.
Pagel, John M.
Wierda, William G.
Anderson, Mary Ann
Rudersdorf, Nikita
Gressick, Lori A.
Montalvo, Nicholas P.
Yang, Jianning
Zhu, Ming
Dunbar, Martin
Cerri, Elisa
Enschede, Sari H.
Humerickhouse, Rod
Roberts, Andrew Warwick
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[27] Polatuzumab Vedotin Combined with Bendamustine (B) and Rituximab (R) or Obinutuzumab (G) in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study
Herrera, Alex F.
Matasar, Matthew J.
Assouline, Sarit
Kamdar, Manali
Mehta, Amitkumar
Fleury, Isabelle
Kim, Won Seog
Kim, Tae Min
Bosch, Francesc
Radford, John A.
Bu, Lilian
Hong, Wan-Jen
Sehn, Laurie H.
BLOOD, 2016, 128 (22)
[28] First interim analysis of a phase 1 study of zanubrutinib (zanu) plus lenalidomide (len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
Zhang, Huilai
Cheng, Ying
Yang, Haiyan
Zhang, Liling
Zou, Liqun
Guo, Ye
Cao, Junning
Huang, Huiqiang
Wang, Zhao
Huang, Sha
Liang, Zhiyu
Lyu, Jiaoyan
Fang, Yiqian
Cohen, Aileen
Zhou, Keshu
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[29] Glofitamab in Patients with relapsed/refractory (R/R) diffuse large B-Cell Lymphoma (DLBCL) and ≥2 prior Lines of Therapy: Key Results of the Phase-II Expansion
Hutchings, M.
Dickinson, M.
Carlo-Stella, C.
Morschhauser, F.
Bachy, E.
Corradini, P.
Iacoboni, G.
Khan, C.
Wrobel, T.
Offner, F.
Trneny, M.
Wu, S. -J.
Cartron, G.
Hertzberg, M.
Sureda, A.
Perez-Callejo, D.
Lundberg, L.
Relf, J.
Clark, E.
Humphrey, K.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 50 - 51
[30] A phase III trial evaluating glofitamab in combination with gemcitabine plus oxaliplatin versus rituximab in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Hertzberg, Mark
Ku, Matthew
Catalani, Olivier
Althaus, Betsy
Simko, Stephen
Gregory, Gareth P.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →